Stockreport

Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers [Yahoo! Finance]

Aprea Therapeutics, Inc.  (APRE) 
PDF trial evaluating highly selective, oral WEE1 inhibitor, for monotherapy treatment of Cyclin E overexpressing cancers including breast and ovarian cancers Update from t [Read more]